Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03515213 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03515213 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 10 participants.
The verdict
NCT03515213, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.
Interventions
- DRUG Placebo
- DRUG Fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-04-27 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03515213
The ClinicalTrials.gov registry entry for NCT03515213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03515213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03515213 about?
NCT03515213 is a clinical study titled "Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease". The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofi...
What is the current status of trial NCT03515213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-04-27. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT03515213?
The interventions under investigation include: Placebo (DRUG), Fenofibrate (DRUG).
Who is sponsoring clinical trial NCT03515213?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.